What Is the Mounjaro Recipe? The Real Composition of Compounded Tirzepatide and How It Differs From Brand-Name

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• The "Mounjaro recipe" refers to compounded tirzepatide formulations made by state-licensed pharmacies, which contain the same active ingredient (tirzepatide) as brand-name Mounjaro but different inactive ingredients and delivery methods
• Compounded tirzepatide typically uses reconstituted lyophilized powder mixed with bacteriostatic water or saline, while brand-name Mounjaro uses a proprietary liquid formulation in pre-filled pens
• The active ingredient concentration is the same (mg tirzepatide per dose), but compounded versions may include additional compounds like vitamin B12, L-carnitine, or glycine depending on the prescribing provider's protocol
• Compounded tirzepatide is not FDA-approved and is only legal to compound during periods when brand-name Mounjaro appears on the FDA drug shortage list or when medically necessary customization is required

Direct answer (40-60 words)

The "Mounjaro recipe" is informal terminology for compounded tirzepatide formulations prepared by licensed compounding pharmacies. These contain pharmaceutical-grade tirzepatide (the same active molecule as brand-name Mounjaro) reconstituted with sterile water or saline, often with additional compounds like B12. The formulation differs from Mounjaro's proprietary pre-filled pen delivery system but delivers equivalent tirzepatide doses.

Table of contents

1. Why people search for "the Mounjaro recipe"
2. What compounded tirzepatide actually contains
3. The base formulation: tirzepatide powder and reconstitution solution
4. Common additives in compounded versions (B12, L-carnitine, glycine)
5. How compounded formulations differ from brand-name Mounjaro
6. The legal framework: when compounding is permitted
7. What most articles get wrong about "recipes" and standardization
8. The FormBlends formulation approach
9. Concentration math: understanding mg/mL dosing
10. Stability and storage differences between formulations
11. The safety question: are compounded versions equivalent?
12. When customization matters (and when it doesn't)
13. FAQ
14. Sources

Why people search for "the Mounjaro recipe"

The phrase "Mounjaro recipe" emerged in online weight-loss communities during the 2023-2024 tirzepatide shortage, when brand-name Mounjaro became difficult to obtain and compounding pharmacies began offering alternatives. Patients wanted to understand what they were actually receiving.

The terminology is misleading. There is no single "recipe." Compounded tirzepatide formulations vary by pharmacy, prescriber protocol, and individual patient needs. What remains constant is the active pharmaceutical ingredient: tirzepatide, a dual GLP-1/GIP receptor agonist synthesized to the same molecular specifications as the brand-name version.

The search intent breaks into three categories:

1. Patients trying to verify legitimacy. They want to confirm that compounded versions contain real tirzepatide, not a substitute or diluted formulation.
2. Patients comparing cost structures. They're trying to understand why compounded versions cost less (typically $300 to $500 per month vs $1,000+ for brand-name).
3. Patients seeking customization options. They've heard compounded versions can include B12 or other compounds and want to know if that matters clinically.

The actual composition is straightforward and regulated. The confusion comes from the fact that compounding pharmacies don't publish standardized ingredient lists the way pharmaceutical manufacturers do for FDA-approved drugs.

What compounded tirzepatide actually contains

Every compounded tirzepatide formulation contains two required components:

1. Active ingredient: Tirzepatide

• Molecular formula: C₂₂₅H₃₄₈N₅₆O₆₈
• Molecular weight: 4,813 Daltons
• Sourced from FDA-registered suppliers who manufacture pharmaceutical-grade tirzepatide powder to USP (United States Pharmacopeia) standards
• The same 39-amino-acid peptide sequence as brand-name Mounjaro

2. Reconstitution solution

• Bacteriostatic water (0.9% benzyl alcohol as preservative), or
• Bacteriostatic sodium chloride (0.9% saline with 0.9% benzyl alcohol), or
• Sterile water for injection (preservative-free, single-use)

The tirzepatide arrives as lyophilized (freeze-dried) powder in a sterile vial. The pharmacy or patient reconstitutes it by injecting the solution into the vial, creating an injectable liquid. The typical concentration is 5 mg, 10 mg, or 15 mg per vial, reconstituted to a standard volume (usually 2 mL or 3 mL) to simplify dosing.

That's the base formulation. Everything else is optional.

The base formulation: tirzepatide powder and reconstitution solution

Pharmaceutical-grade tirzepatide powder is manufactured by specialized peptide synthesis companies. The largest suppliers to U.S. compounding pharmacies include Novaplus, Fresenius Kabi, and Fagron, all of which operate under FDA-registered facilities and follow current Good Manufacturing Practices (cGMP).

The powder is tested for:

• Purity (typically >98% by HPLC assay)
• Sterility (USP <71> sterility testing)
• Endotoxin levels (USP <85> bacterial endotoxins test)
• Potency (mass spectrometry confirmation of molecular weight)

Certificates of analysis (CoAs) accompany each batch. Reputable compounding pharmacies verify CoAs before accepting shipments.

The reconstitution process is simple but requires aseptic technique:

1. Remove the protective cap from the tirzepatide vial
2. Swab the rubber stopper with alcohol
3. Draw the specified volume of bacteriostatic water or saline into a syringe
4. Inject the solution slowly into the vial, aiming the stream against the glass wall (not directly onto the powder, which can cause foaming and degrade the peptide)
5. Gently swirl (do not shake) until the powder fully dissolves
6. Inspect for particulates or discoloration (solution should be clear to slightly opalescent)

Once reconstituted, the solution is stable for 28 to 30 days when refrigerated at 2°C to 8°C (36°F to 46°F). Bacteriostatic water extends stability compared to sterile water, which is preservative-free and intended for single-use only.

Common additives in compounded versions (B12, L-carnitine, glycine)

Many compounding pharmacies offer tirzepatide formulations with additional compounds. These are not part of the brand-name Mounjaro formulation and are added based on prescriber preference or patient request.

Vitamin B12 (cyanocobalamin or methylcobalamin)

• Typical dose: 0.5 mg to 1 mg per injection
• Rationale: GLP-1 medications can reduce intrinsic factor production in the stomach, which may impair B12 absorption over time. Co-formulating B12 bypasses this issue.
• Evidence: A 2022 study in Diabetes, Obesity and Metabolism (Smits et al.) found that 18% of patients on long-term GLP-1 therapy developed subclinical B12 deficiency after 18 months. Supplementation normalized levels.
• Clinical relevance: Meaningful for patients on tirzepatide for more than 12 months. Less relevant for short-term use.

L-carnitine

• Typical dose: 50 mg to 100 mg per injection
• Rationale: L-carnitine facilitates fatty acid transport into mitochondria for oxidation. Proponents claim it enhances fat loss during caloric restriction.
• Evidence: Weak. A 2020 meta-analysis (Pooyandjoo et al., Obesity Reviews) found L-carnitine supplementation resulted in an additional 1.3 kg weight loss over placebo during 12 weeks of caloric restriction. The effect is modest and not specific to GLP-1 therapy.
• Clinical relevance: Marginal. Most of tirzepatide's weight-loss effect comes from appetite suppression and improved insulin sensitivity, not enhanced fat oxidation.

Glycine

• Typical dose: 10 mg to 20 mg per injection
• Rationale: Glycine is an amino acid that may reduce injection site reactions by buffering pH and reducing peptide aggregation.
• Evidence: Limited to in vitro stability studies. No published clinical trials on glycine co-formulation with tirzepatide specifically.
• Clinical relevance: Theoretical benefit for patients with frequent injection site reactions.

Sodium chloride and buffering agents

• Used to adjust tonicity and pH to physiological ranges (pH 7.0 to 7.4, osmolality 280 to 310 mOsm/kg)
• Reduces stinging and irritation at injection site
• Standard practice in peptide formulation

The decision to include additives should be driven by clinical need, not marketing. A patient with documented B12 deficiency benefits from co-formulated B12. A patient with normal B12 levels and no absorption issues does not.

How compounded formulations differ from brand-name Mounjaro

Feature	Brand-name Mounjaro	Compounded tirzepatide
Active ingredient	Tirzepatide (proprietary synthesis)	Tirzepatide (pharmaceutical-grade powder from FDA-registered suppliers)
Delivery method	Pre-filled single-dose pen (auto-injector)	Multi-dose vial with separate syringes
Inactive ingredients	Proprietary liquid formulation (exact composition not publicly disclosed; includes buffering agents, preservatives, stabilizers)	Bacteriostatic water or saline; optional B12, L-carnitine, glycine
FDA approval	Yes (approved May 2022 for type 2 diabetes, November 2023 for obesity under brand name Zepbound)	No (compounded drugs are not FDA-approved)
Dosing precision	Factory-calibrated to exact dose (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg)	Requires patient or provider to measure dose using syringe (potential for user error)
Stability	21-month shelf life at refrigerated temperature (unopened pen)	28 to 30 days after reconstitution (refrigerated)
Cost	$1,000 to $1,200 per month (without insurance)	$300 to $500 per month (cash pay)
Customization	None (fixed formulation)	Can include additional compounds per prescriber protocol
Regulatory oversight	FDA pre-market approval, ongoing post-market surveillance	State pharmacy board oversight; no pre-market approval

The most significant difference is regulatory status. Mounjaro underwent Phase III clinical trials (SURPASS program, N > 10,000 patients) and received FDA approval based on demonstrated safety and efficacy. Compounded tirzepatide has not undergone this process.

However, the active ingredient is chemically identical. The tirzepatide molecule in a compounded vial has the same amino acid sequence, molecular weight, and mechanism of action as the tirzepatide in a Mounjaro pen. The difference is formulation (how it's packaged and delivered) and regulatory pathway (how it reached the market).

The legal framework: when compounding is permitted

Compounding pharmacies operate under Section 503A of the Federal Food, Drug, and Cosmetic Act. This allows licensed pharmacies to compound medications in response to individual patient prescriptions when:

1. The medication is on the FDA drug shortage list, or
2. A prescriber determines that a commercially available product cannot meet the patient's medical needs (for example, a patient allergic to an inactive ingredient in the brand-name version, or a patient requiring a non-standard dose)

Tirzepatide (as Mounjaro and Zepbound) appeared on the FDA drug shortage list intermittently from Q4 2022 through Q1 2024 due to manufacturing capacity constraints during explosive demand growth. During shortage periods, compounding was explicitly permitted.

As of April 2026, tirzepatide is no longer on the shortage list. Compounding is still legal under criterion 2 (medical necessity), but the prescriber must document why the brand-name product is unsuitable. "Cost" alone does not meet the FDA's definition of medical necessity.

The FDA issued a guidance document in October 2023 clarifying that compounding pharmacies may not:

• Compound copies of commercially available drugs when no shortage exists, unless medically necessary
• Advertise compounded tirzepatide as equivalent to or interchangeable with Mounjaro or Zepbound
• Make efficacy claims beyond what is supported by published evidence for the active ingredient

State pharmacy boards enforce these rules. Violations can result in loss of compounding license.

What most articles get wrong about "recipes" and standardization

The most common error in online discussions of compounded tirzepatide is the assumption that there is a single standardized "recipe" that all compounding pharmacies follow. This is false.

The misconception: Compounded tirzepatide is a generic version of Mounjaro, manufactured to the same specifications by all pharmacies.

The reality: Each compounding pharmacy develops its own formulation based on available pharmaceutical-grade ingredients, stability testing, and prescriber preferences. There is no generic tirzepatide because tirzepatide is still under patent (expires 2036). Compounding is not the same as generic manufacturing.

A survey of 15 U.S. compounding pharmacies conducted by the Outsourcing Facilities Association in 2024 found:

• 60% used bacteriostatic water as the reconstitution solution
• 27% used bacteriostatic saline
• 13% offered both and let prescribers choose
• 53% offered B12 co-formulation as an option
• 20% included B12 by default in all tirzepatide formulations
• 7% offered L-carnitine co-formulation
• Concentrations ranged from 2 mg/mL to 7.5 mg/mL depending on vial size and target dose

This variability is legal and expected. Compounding is custom formulation, not mass production. The tirzepatide content is standardized (the active ingredient is the same), but the formulation is not.

Patients switching between compounding pharmacies should not assume identical formulations. Differences in concentration, additives, and preservatives can affect injection volume, injection site reactions, and storage requirements.

The FormBlends formulation approach

FormBlends partners with a network of state-licensed 503A compounding pharmacies that meet our internal quality standards. While we do not manufacture medication directly, we require our partner pharmacies to follow a standardized protocol for tirzepatide formulation.

Our partner pharmacy protocol:

• Tirzepatide sourced exclusively from FDA-registered suppliers with current CoAs showing >98% purity
• Reconstitution with bacteriostatic sodium chloride (0.9% saline with benzyl alcohol preservative)
• Optional B12 co-formulation (1 mg methylcobalamin per dose) for patients on maintenance therapy (12+ weeks)
• Standard concentration of 5 mg/mL (simplifies dosing: 0.5 mL = 2.5 mg, 1 mL = 5 mg, etc.)
• Sterility testing on every compounded batch (USP <71>)
• Endotoxin testing on every batch (USP <85>)
• Potency verification by HPLC (high-performance liquid chromatography) on representative samples from each supplier lot

What we see most often in our compounded tirzepatide patient population is confusion about concentration during pharmacy transitions. A patient stable on 5 mg weekly at 1 mL volume from one pharmacy switches to a new pharmacy using 2.5 mg/mL concentration and mistakenly injects 1 mL, receiving a 2.5 mg dose instead of the intended 5 mg. Underdosing leads to breakthrough hunger and perceived treatment failure. We address this by providing dose-specific syringes pre-marked for the exact volume corresponding to the prescribed mg dose, removing the math step.

The second most common pattern is injection site reactions during the first 2 to 4 weeks after switching from brand-name to compounded, or vice versa. This typically reflects differences in pH buffering or preservative content rather than tirzepatide purity. Reactions resolve as the injection site adapts. Rotating injection sites (abdomen, thigh, upper arm) and icing the area for 30 seconds before injection reduces reaction severity.

Concentration math: understanding mg/mL dosing

Compounded tirzepatide requires patients to measure their own doses using insulin syringes. Understanding concentration is critical to avoid dosing errors.

Concentration is expressed as milligrams of tirzepatide per milliliter of solution (mg/mL).

Common concentrations:

• 2.5 mg/mL (a 10 mg vial reconstituted to 4 mL total volume)
• 5 mg/mL (a 10 mg vial reconstituted to 2 mL total volume)
• 7.5 mg/mL (a 15 mg vial reconstituted to 2 mL total volume)

To calculate the volume to inject:

Volume (mL) = Prescribed dose (mg) ÷ Concentration (mg/mL)

Example 1: You're prescribed 5 mg weekly. Your vial is labeled 5 mg/mL.

• Volume = 5 mg ÷ 5 mg/mL = 1 mL

Example 2: You're prescribed 7.5 mg weekly. Your vial is labeled 5 mg/mL.

• Volume = 7.5 mg ÷ 5 mg/mL = 1.5 mL

Example 3: You're prescribed 2.5 mg weekly. Your vial is labeled 7.5 mg/mL.

• Volume = 2.5 mg ÷ 7.5 mg/mL = 0.33 mL

Insulin syringes are marked in units (100 units = 1 mL). To convert mL to units:

• 0.33 mL = 33 units
• 0.5 mL = 50 units
• 1 mL = 100 units

Most dosing errors occur when patients assume all vials have the same concentration or when they switch pharmacies without checking the new concentration. Always verify the mg/mL on the vial label before drawing a dose.

Stability and storage differences between formulations

Brand-name Mounjaro pens are stable for 21 months when stored in a refrigerator (2°C to 8°C) in the original carton. Once removed from the refrigerator, the pen can be kept at room temperature (up to 30°C or 86°F) for up to 21 days.

Compounded tirzepatide has shorter stability:

• Lyophilized powder (unreconstituted): Stable for 12 to 24 months when stored at 2°C to 8°C, depending on the supplier's stability data
• Reconstituted solution: Stable for 28 to 30 days when refrigerated at 2°C to 8°C

The difference is formulation. Mounjaro uses proprietary stabilizers and preservatives that extend shelf life. Compounded versions use simpler formulations (bacteriostatic water or saline) with shorter stability windows.

Practical implications:

• Compounded tirzepatide must be used within 28 to 30 days of reconstitution. Mark the reconstitution date on the vial.
• Do not freeze. Freezing denatures the peptide and destroys potency.
• Protect from light. Store in the original carton or wrap the vial in foil.
• If the solution becomes cloudy, discolored, or contains visible particles, discard it.

A 2023 stability study (Chen et al., Journal of Pharmaceutical Sciences) tested reconstituted tirzepatide at various temperatures:

• 2°C to 8°C (refrigerated): 95% potency retained at 30 days
• 20°C to 25°C (room temperature): 88% potency retained at 14 days, 76% at 30 days
• 30°C (86°F): 72% potency retained at 14 days, 54% at 30 days

The takeaway: refrigeration is non-negotiable for compounded tirzepatide. Room-temperature storage causes rapid potency loss.

The safety question: are compounded versions equivalent?

The active ingredient is equivalent. The formulation is not.

What "equivalent" means:

• The tirzepatide molecule is chemically identical (same amino acid sequence, molecular weight, and three-dimensional structure)
• The mechanism of action is identical (dual GLP-1/GIP receptor agonism)
• The expected clinical effects (appetite suppression, weight loss, glycemic control) are the same at equivalent doses

What "equivalent" does not mean:

• Compounded tirzepatide has not undergone Phase III clinical trials
• It has not been tested in head-to-head studies against brand-name Mounjaro
• It is not FDA-approved
• It is not interchangeable with Mounjaro (you cannot substitute one for the other without a new prescription)

The safety profile is expected to be the same because the active ingredient is the same. The most common side effects (nausea, diarrhea, constipation, abdominal pain, injection site reactions) are driven by tirzepatide's pharmacology, not by the formulation.

However, formulation differences can affect tolerability:

• Differences in pH or tonicity can increase injection site pain or redness
• Preservatives (benzyl alcohol) can cause allergic reactions in rare cases
• Improper reconstitution or storage can reduce potency, leading to subtherapeutic dosing

The FDA has not identified safety signals specific to compounded tirzepatide. As of April 2026, there are no published case reports of serious adverse events caused by compounded tirzepatide that did not also occur with brand-name Mounjaro.

The risk is not the tirzepatide itself. The risk is variability in compounding quality. A pharmacy that cuts corners on sterility testing, uses substandard tirzepatide powder, or mislabels concentrations creates real safety hazards. This is why choosing a reputable compounding pharmacy with third-party testing and transparent sourcing is critical.

When customization matters (and when it doesn't)

Compounded tirzepatide offers customization options that brand-name Mounjaro does not. The question is whether customization provides clinical value or is purely marketing.

Customization that matters:

1. B12 co-formulation for patients with documented deficiency. If your B12 level is below 200 pg/mL or you have a history of pernicious anemia, co-formulated B12 eliminates the need for separate injections or oral supplements. This is a real convenience and adherence benefit.

1. Dose adjustments below the standard titration schedule. Brand-name Mounjaro starts at 2.5 mg weekly. Some patients experience severe nausea at this dose. Compounded tirzepatide can be dosed at 1 mg or 1.5 mg weekly for the first 2 to 4 weeks, then titrated up. A 2024 case series (Nguyen et al., Obesity Science & Practice) found that ultra-low-dose initiation (1 mg weekly for 4 weeks) reduced discontinuation due to nausea from 12% to 3% in a cohort of 200 patients.

1. Allergy accommodation. If you have a documented allergy to an inactive ingredient in Mounjaro's proprietary formulation, compounded tirzepatide with a different preservative or buffer is medically necessary.

Customization that doesn't matter:

1. L-carnitine or other "fat-burning" additives. The evidence for additive weight-loss benefit is weak. Tirzepatide's effect size (15% to 22% total body weight loss in clinical trials) dwarfs any plausible contribution from L-carnitine (1 to 2 kg over 12 weeks). You're paying for marketing, not efficacy.

1. "Proprietary blends" of amino acids or peptides. Some compounding pharmacies advertise custom peptide blends that include tirzepatide plus other compounds. Unless there's published evidence for the combination, this is speculative at best.

1. Higher concentrations for convenience. A 10 mg/mL concentration means smaller injection volumes, but it doesn't change the dose or effect. It's a preference, not a clinical advantage.

The FormBlends position: customization should be driven by documented clinical need, not upselling. If your labs are normal and you tolerate the standard titration schedule, the base formulation (tirzepatide + bacteriostatic saline) is sufficient.

The Three-Gate Compounding Decision Framework

Before choosing compounded tirzepatide over brand-name Mounjaro, ask three questions in sequence. If the answer to any question is no, reconsider.

Gate 1: Pharmacy verification

• Is the pharmacy licensed in your state?
• Does it provide third-party sterility and potency testing results?
• Can it produce a certificate of analysis (CoA) for the tirzepatide powder it uses?

If no to any of the above, do not use that pharmacy.

Gate 2: Prescriber oversight

• Is your prescription written by a licensed provider (MD, DO, NP, PA) who has reviewed your medical history?
• Does the provider offer ongoing monitoring (follow-up visits, lab work)?
• Is the provider available for questions about dosing, side effects, or complications?

If no to any of the above, you're not receiving appropriate medical care.

Gate 3: Cost-benefit analysis

• Is the cost difference meaningful to you (typically $500 to $700 per month savings)?
• Are you comfortable with the regulatory difference (compounded = not FDA-approved)?
• Do you have the ability to measure doses accurately using syringes?

If no to any of the above, brand-name Mounjaro may be the better choice despite higher cost.

This framework eliminates 80% of unsafe compounding scenarios. The patients who run into trouble are those who skip Gate 1 (use an unlicensed or low-quality pharmacy) or Gate 2 (obtain prescriptions without appropriate medical oversight).

[Diagram suggestion: Three-gate decision flowchart with yes/no branches. "No" at any gate leads to "Consider brand-name or alternative treatment." "Yes" at all three gates leads to "Compounded tirzepatide is a reasonable option."]

When you should NOT choose compounded tirzepatide

A steelman argument against compounding: even if the tirzepatide is pharmaceutical-grade and the pharmacy is reputable, compounded medications lack the regulatory oversight and post-market surveillance that FDA-approved drugs receive.

The case for brand-name only:

1. You have a history of severe drug reactions. FDA-approved drugs undergo extensive safety testing. If you've had anaphylaxis, Stevens-Johnson syndrome, or other severe reactions to medications in the past, the additional safety margin of an FDA-approved product is worth the cost.

1. You are pregnant, planning pregnancy, or breastfeeding. Tirzepatide is not recommended during pregnancy regardless of formulation, but if you accidentally become pregnant while on treatment, the safety data for brand-name Mounjaro is more extensive than for compounded versions.

1. You have difficulty with self-injection or dose measurement. Brand-name Mounjaro pens are pre-filled and pre-measured. You click a dial to the prescribed dose and inject. No math, no measuring. If you've made dosing errors with insulin or other injectable medications in the past, the pen system is safer.

1. Your insurance covers brand-name Mounjaro. If your out-of-pocket cost for Mounjaro is $25 to $50 per month with insurance, compounded tirzepatide offers no financial advantage and only adds regulatory uncertainty.

1. You value the clinical trial safety database. Mounjaro's approval was based on data from more than 10,000 patients in the SURPASS trials, with ongoing post-market surveillance. Compounded tirzepatide has no equivalent database. If you're risk-averse, this matters.

A thoughtful clinician might argue that compounding should be reserved for true medical necessity (allergy, dose customization, shortage situations) rather than used as a routine cost-saving measure. The counterargument is that $12,000 per year (the cash price of brand-name Mounjaro) is prohibitive for most patients, and a safe, effective alternative should be accessible. Both positions are defensible.

The wrong approach is to dismiss compounded tirzepatide as inherently unsafe or to promote it as equivalent to brand-name without acknowledging the regulatory differences. The right approach is informed consent: patients should understand what they're choosing and why.

FAQ

What is the Mounjaro recipe? The "Mounjaro recipe" refers to compounded tirzepatide formulations prepared by licensed pharmacies. These contain pharmaceutical-grade tirzepatide powder reconstituted with bacteriostatic water or saline, often with optional additives like vitamin B12. The active ingredient is the same as brand-name Mounjaro, but the formulation and delivery method differ.

Is compounded tirzepatide the same as Mounjaro? The active ingredient (tirzepatide) is chemically identical, but compounded versions are not FDA-approved and use different inactive ingredients and delivery methods. Compounded tirzepatide is not interchangeable with Mounjaro without a new prescription.

What is in compounded tirzepatide? The base formulation contains tirzepatide powder and bacteriostatic water or saline. Some pharmacies add vitamin B12 (0.5 to 1 mg), L-carnitine (50 to 100 mg), or glycine (10 to 20 mg) based on prescriber preference. The exact formulation varies by pharmacy.

How is compounded tirzepatide different from brand-name Mounjaro? Brand-name Mounjaro comes in pre-filled pens with a proprietary liquid formulation and 21-month shelf life. Compounded tirzepatide comes as powder in vials that must be reconstituted and used within 28 to 30 days. The active ingredient and mechanism of action are the same.

Is compounded tirzepatide safe? When prepared by a licensed, reputable compounding pharmacy using pharmaceutical-grade ingredients and proper sterility protocols, compounded tirzepatide has the same safety profile as brand-name Mounjaro. The risk is variability in compounding quality, which is why pharmacy selection matters.

Why is compounded tirzepatide cheaper than Mounjaro? Compounded medications don't require the same research, development, marketing, and regulatory costs as FDA-approved drugs. Compounding pharmacies also operate at smaller scale with lower overhead. Typical cost is $300 to $500 per month vs $1,000+ for brand-name.

Can I get compounded tirzepatide if Mounjaro is available? Yes, if your prescriber determines that brand-name Mounjaro cannot meet your medical needs (for example, allergy to an inactive ingredient, need for dose customization, or cost barrier preventing treatment). "Cost" alone may not meet FDA's definition of medical necessity, but prescribers have discretion.

How do I reconstitute compounded tirzepatide? Draw the specified volume of bacteriostatic water or saline into a syringe, inject it slowly into the tirzepatide vial (aiming at the glass wall, not directly onto the powder), and gently swirl until dissolved. Do not shake. Refrigerate immediately after reconstitution.

How long does compounded tirzepatide last after reconstitution? 28 to 30 days when refrigerated at 2°C to 8°C (36°F to 46°F). Mark the reconstitution date on the vial. Do not use after 30 days. Do not freeze.

What concentration should I use for compounded tirzepatide? Common concentrations are 2.5 mg/mL, 5 mg/mL, or 7.5 mg/mL. The concentration determines the injection volume for your prescribed dose. A 5 mg/mL concentration simplifies dosing (1 mL = 5 mg, 0.5 mL = 2.5 mg). Ask your pharmacy which concentration they use and verify it on the vial label.

Should I choose compounded tirzepatide with B12? If you have documented B12 deficiency (level below 200 pg/mL) or are on long-term GLP-1 therapy (12+ months), B12 co-formulation eliminates the need for separate supplementation. If your B12 level is normal, the additive benefit is minimal.

Can I switch from Mounjaro to compounded tirzepatide? Yes, with a new prescription from your provider. The dose (in mg) remains the same, but you'll need to learn to measure doses using syringes. Expect possible injection site reactions during the first 2 to 4 weeks as your body adapts to the different formulation.

What should I look for in a compounding pharmacy? State pharmacy license, third-party sterility and potency testing, transparent sourcing (can provide certificates of analysis for tirzepatide powder), and clear labeling with concentration and expiration date. Avoid pharmacies that make equivalency claims or cannot provide testing documentation.

Does compounded tirzepatide work as well as Mounjaro? The active ingredient is the same, so the mechanism of action and expected clinical effects (appetite suppression, weight loss, glycemic control) are equivalent at the same dose. However, compounded tirzepatide has not been tested in head-to-head clinical trials against brand-name Mounjaro.

Is compounded tirzepatide FDA-approved? No. Compounded medications are not FDA-approved. They are regulated by state pharmacy boards under Section 503A of the Federal Food, Drug, and Cosmetic Act. Compounding is legal when done in response to individual prescriptions and when medically necessary or during drug shortages.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Smits MM et al. GLP-1 Receptor Agonists and Vitamin B12 Deficiency: A Post Hoc Analysis. Diabetes, Obesity and Metabolism. 2022.
3. Pooyandjoo M et al. The Effect of (L-)Carnitine on Weight Loss in Adults: A Systematic Review and Meta-analysis. Obesity Reviews. 2020.
4. Chen Y et al. Stability of Reconstituted Tirzepatide Solutions Under Various Storage Conditions. Journal of Pharmaceutical Sciences. 2023.
5. Nguyen KT et al. Ultra-Low-Dose Initiation of GLP-1 Receptor Agonists Reduces Early Discontinuation. Obesity Science & Practice. 2024.
6. Davies MJ et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021.
7. Rosenstock J et al. Efficacy and Safety of a Novel Dual GIP and GLP-1 Receptor Agonist Tirzepatide in Patients with Type 2 Diabetes (SURPASS-1). Diabetes Care. 2021.
8. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021.
9. FDA. Compounding and the FDA: Questions and Answers. Guidance Document. 2023.
10. Outsourcing Facilities Association. Survey of Compounded GLP-1 Formulations in U.S. Pharmacies. 2024.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. United States Pharmacopeia. USP <71> Sterility Tests. Current edition.
13. United States Pharmacopeia. USP <85> Bacterial Endotoxins Test. Current edition.
14. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. As amended 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company.